
|Videos|August 7, 2021
Evaluating risuteganib for dry eye disease treatment
Author(s)David Hutton, Alex Delaney-Gesing
Advertisement
Eric Donnenfeld, MD, of Ophthalmic Consultants of Long Island (Garden City, NY), discusses highlights from his presentation of trial results analyzing risuteganib as a potential treatment for dry eye disease.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Ocugen publishes phase 1 GARDian1 gene therapy data for Stargardt disease
2
FDA grants Fast Track Designation to Complement Therapeutics’ CTx001 for geographic atrophy
3
Study shows significant ocular changes following hemodialysis
4
Nanoscope secures new US patent for Multi-Characteristic Opsin (MCO) technology platform
5













































